[Federal Register Volume 89, Number 67 (Friday, April 5, 2024)]
[Notices]
[Page 24011]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2024-07268]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA-2024-P-0105]
Determination That GLUCOTROL (Glipizide) Tablets, 5 Milligrams
and 10 Milligrams, Were Not Withdrawn From Sale for Reasons of Safety
or Effectiveness
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA or Agency) has
determined that GLUCOTROL (glipizide) tablets, 5 milligrams (mg) and 10
mg, were not withdrawn from sale for reasons of safety or
effectiveness. This determination means that FDA will not begin
procedures to withdraw approval of abbreviated new drug applications
(ANDAs) that refer to these drug products, and it will allow FDA to
continue to approve ANDAs that refer to these products as long as they
meet relevant legal and regulatory requirements.
FOR FURTHER INFORMATION CONTACT: Swati Rawani, Center for Drug
Evaluation and Research, Food and Drug Administration, 10903 New
Hampshire Ave., Bldg. 51, Rm. 6221, Silver Spring, MD 20993-0002, 240-
402-9917, [email protected].
SUPPLEMENTARY INFORMATION: Section 505(j) of the Federal Food, Drug,
and Cosmetic Act (FD&C Act) (21 U.S.C. 355(j)) allows the submission of
an ANDA to market a generic version of a previously approved drug
product. To obtain approval, the ANDA applicant must show, among other
things, that the generic drug product: (1) has the same active
ingredient(s), dosage form, route of administration, strength,
conditions of use, and (with certain exceptions) labeling as the listed
drug, which is a version of the drug that was previously approved, and
(2) is bioequivalent to the listed drug. ANDA applicants do not have to
repeat the extensive clinical testing otherwise necessary to gain
approval of a new drug application (NDA).
Section 505(j)(7) of the FD&C Act requires FDA to publish a list of
all approved drugs. FDA publishes this list as part of the ``Approved
Drug Products With Therapeutic Equivalence Evaluations,'' which is
known generally as the ``Orange Book.'' Under FDA regulations, drugs
are removed from the list if the Agency withdraws or suspends approval
of the drug's NDA or ANDA for reasons of safety or effectiveness or if
FDA determines that the listed drug was withdrawn from sale for reasons
of safety or effectiveness (21 CFR 314.162).
A person may petition the Agency to determine, or the Agency may
determine on its own initiative, whether a listed drug was withdrawn
from sale for reasons of safety or effectiveness. This determination
may be made at any time after the drug has been withdrawn from sale,
but must be made prior to approving an ANDA that refers to the listed
drug (Sec. 314.161 (21 CFR 314.161)). FDA may not approve an ANDA that
does not refer to a listed drug.
GLUCOTROL (glipizide) tablets, 5 mg and 10 mg, are the subject of
NDA 017783, held by Pfizer Inc., and initially approved on May 8, 1984.
GLUCOTROL is indicated as an adjunct to diet and exercise to improve
glycemic control in adults with type 2 diabetes mellitus.
In a letter dated June 30, 2022, Pfizer Inc., notified FDA that
GLUCOTROL (glipizide) tablets, 5 mg and 10 mg, were being discontinued,
and FDA moved these drug products to the ``Discontinued Drug Product
List'' section of the Orange Book.
Graviti Pharmaceuticals Private Limited submitted a citizen
petition dated January 3, 2024, Docket No. FDA-2024-P-0105, under 21
CFR 10.30, requesting that the Agency determine whether GLUCOTROL
(glipizide) tablets, 5 mg and 10 mg, were withdrawn from sale for
reasons of safety or effectiveness.
After considering the citizen petition and reviewing Agency records
and based on the information we have at this time, FDA has determined
under Sec. 314.161 that GLUCOTROL (glipizide) tablets, 5 mg and 10 mg,
were not withdrawn for reasons of safety or effectiveness. The
petitioner has identified no data or other information suggesting that
GLUCOTROL (glipizide) tablets, 5 mg and 10 mg, were withdrawn for
reasons of safety or effectiveness. We have carefully reviewed our
files for records concerning the withdrawal of GLUCOTROL (glipizide)
tablets, 5 mg and 10 mg, from sale. We have also independently
evaluated relevant literature and data for possible postmarketing
adverse events. We have reviewed the available evidence and determined
that these drug products were not withdrawn from sale for reasons of
safety or effectiveness.\1\
---------------------------------------------------------------------------
\1\ FDA previously determined that GLUCOTROL (glipizide)
tablets, 2.5 mg, were not withdrawn from sale for reasons of safety
or effectiveness (87 FR 28015, May 10, 2022).
---------------------------------------------------------------------------
Accordingly, the Agency will continue to list GLUCOTROL (glipizide)
tablets, 5 mg and 10 mg, in the ``Discontinued Drug Product List''
section of the Orange Book. The ``Discontinued Drug Product List''
delineates, among other items, drug products that have been
discontinued from marketing for reasons other than safety or
effectiveness. FDA will not begin procedures to withdraw approval of
approved ANDAs that refer to these drug products. Additional ANDAs for
these drug products may also be approved by the Agency as long as they
meet all other legal and regulatory requirements for the approval of
ANDAs. If FDA determines that labeling for these drug products should
be revised to meet current standards, the Agency will advise ANDA
applicants to submit such labeling.
Dated: April 2, 2024.
Lauren K. Roth,
Associate Commissioner for Policy.
[FR Doc. 2024-07268 Filed 4-4-24; 8:45 am]
BILLING CODE 4164-01-P